Previous 10 | Next 10 |
Meaningful, durable reductions of HBsAg were seen, both in participants who received VTP-300 alone and in combination with a low-dose PD-1 inhibitor Two patients developed a non-detectable HBsAg level, which continued eight months after last dose A robust T cell response was gener...
Evaluating safety and efficacy of combining AB-729, VTP-300, nucleos(t)ide analogues and nivolumab (Opdivo®) WARMINSTER, Pa., June 21, 2023 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-stage biopha...
OXFORD, United Kingdom, June 12, 2023 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ: VACC) (the Company, we or us), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics for the treatment of autoimmunity, chronic infectious diseases and cancer...
2023-05-17 15:17:32 ET Summary Preliminary results from phase 2a study, using AB-729 + Nucleoside analogue + PEG-IFN-2a for the treatment of patients with Hepatitis B, are expected in Q2 of 2023. Results from phase 2a study, using AB-729 + Nucleoside analogue + VTP-300, for the tr...
2023-05-12 09:59:54 ET Vaccitech press release ( NASDAQ: VACC ): Q1 GAAP EPS of -$0.48 beats by $0.10 . Revenue of $0.47M (-96.9% Y/Y) misses by $0.93M . For further details see: Vaccitech GAAP EPS of -$0.48 beats by $0.10, revenue of $0.47M misses by $0.93M
OXFORD, United Kingdom, May 12, 2023 (GLOBE NEWSWIRE) -- Vaccitech plc (NASDAQ: VACC) (the Company, we or us), a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics and vaccines for the treatment and prevention of infectious diseases, auto...
VTP-200 was generally well-tolerated and was administered with no product-related grade 3 unsolicited adverse events and no product-related serious adverse events (SAEs) in women with low grade human papillomavirus-related cervical lesions Interim data showed encouraging initial...
2023-03-28 09:04:01 ET Vaccitech ( NASDAQ: VACC ) is down 10% in premarket trading Tuesday despite posting top-line phase 1b/2a data on an immunotherapy for hepatitis B virus (HBV) that met primary and secondary endpoints. The open-label study examined VTP-300 in ...
Completed Phase 1b/2a trial of VTP-300 met its primary and secondary endpoints VTP-300 is the first antigen-specific immunotherapy shown to induce sustained reductions in Hepatitis B surface antigen (HBsAg) Results will be presented at the upcoming European Association for the S...
2023-03-24 12:20:59 ET Gainers: Silvergate Capital Corporation ( SI ) +66% . NaaS Technology ( NAAS ) +36% . Assure Holdings ( IONM ) +21% . Dermata Therapeutics ( DRMA ) +21% . ReNew Energy Global ( RNW ) +20% . GH Research ...
News, Short Squeeze, Breakout and More Instantly...
Vaccitech plc Company Name:
VACC Stock Symbol:
NASDAQ Market:
New Corporate Brand to be Unveiled at AASLD Liver Meeting® 2023 with Interim Data OXFORD, United Kingdom, Nov. 06, 2023 (GLOBE NEWSWIRE) -- Barinthus Biotherapeutics plc (NASDAQ: BRNS), formerly Vaccitech plc (NASDAQ: VACC), a clinical-stage biopharmaceutical company developing nov...
2023-09-27 06:52:40 ET DENVER, Colo., Sept 27, 2023 ( www.247marketnews.com )- The following stocks are the top performing U.S. stocks over the past week; Vaccitech (NASDAQ: VACC), Siyata Mobile (NASDAQ: SYTA), Soleno Therapeutics (NASDAQ: SLNO), Femasys (NASDAQ: FEMY), Immunovant (NASD...
2023-09-26 07:38:47 ET DENVER, Colo., Sept 26, 2023 ( www.247marketnews.com )- The following stocks are the top performing U.S. stocks over the past week; Vaccitech (NASDAQ:VACC), Lifezone Metals (NYSE:LZM), Globus Maritime Ltd. (NASDAQ:GLBS), Siyata Mobile (NASDAQ:SYTA), ESS Tech (NYSE...